773 related articles for article (PubMed ID: 31912280)
61. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.
Gomperts SN; Locascio JJ; Makaretz SJ; Schultz A; Caso C; Vasdev N; Sperling R; Growdon JH; Dickerson BC; Johnson K
JAMA Neurol; 2016 Nov; 73(11):1334-1341. PubMed ID: 27654968
[TBL] [Abstract][Full Text] [Related]
62. Clinical correlates of pathology in the claustrum in Parkinson's disease and dementia with Lewy bodies.
Kalaitzakis ME; Pearce RK; Gentleman SM
Neurosci Lett; 2009 Sep; 461(1):12-5. PubMed ID: 19523504
[TBL] [Abstract][Full Text] [Related]
63. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.
Mollenhauer B; Caspell-Garcia CJ; Coffey CS; Taylor P; Shaw LM; Trojanowski JQ; Singleton A; Frasier M; Marek K; Galasko D;
Neurology; 2017 Nov; 89(19):1959-1969. PubMed ID: 29030452
[TBL] [Abstract][Full Text] [Related]
64. Prevalence, distribution, and severity of cerebral amyloid angiopathy differ between Lewy body diseases and Alzheimer's disease.
Walker L; Simpson H; Thomas AJ; Attems J
Acta Neuropathol Commun; 2024 Feb; 12(1):28. PubMed ID: 38360761
[TBL] [Abstract][Full Text] [Related]
65. Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies.
Chatterjee M; van Steenoven I; Huisman E; Oosterveld L; Berendse H; van der Flier WM; Del Campo M; Lemstra AW; van de Berg WDJ; Teunissen CE
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32806791
[TBL] [Abstract][Full Text] [Related]
66. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies.
Brockmann K; Quadalti C; Lerche S; Rossi M; Wurster I; Baiardi S; Roeben B; Mammana A; Zimmermann M; Hauser AK; Deuschle C; Schulte C; Waniek K; Lachmann I; Sjödin S; Brinkmalm A; Blennow K; Zetterberg H; Gasser T; Parchi P
Acta Neuropathol Commun; 2021 Oct; 9(1):175. PubMed ID: 34717775
[TBL] [Abstract][Full Text] [Related]
67. Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies.
Llorens F; Schmitz M; Varges D; Kruse N; Gotzmann N; Gmitterová K; Mollenhauer B; Zerr I
J Neurol; 2016 Nov; 263(11):2271-2277. PubMed ID: 27544498
[TBL] [Abstract][Full Text] [Related]
68. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
Goldman JG; Andrews H; Amara A; Naito A; Alcalay RN; Shaw LM; Taylor P; Xie T; Tuite P; Henchcliffe C; Hogarth P; Frank S; Saint-Hilaire MH; Frasier M; Arnedo V; Reimer AN; Sutherland M; Swanson-Fischer C; Gwinn K; ; Kang UJ
Mov Disord; 2018 Feb; 33(2):282-288. PubMed ID: 29205509
[TBL] [Abstract][Full Text] [Related]
69. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
Shea YF; Ha J; Chu LW
Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
[TBL] [Abstract][Full Text] [Related]
70. Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders.
Patterson L; Rushton SP; Attems J; Thomas AJ; Morris CM
Brain Pathol; 2019 Jul; 29(4):544-557. PubMed ID: 30582885
[TBL] [Abstract][Full Text] [Related]
71. A Comparison of Cerebrospinal Fluid Beta-Amyloid and Tau in Idiopathic Normal Pressure Hydrocephalus and Neurodegenerative Dementias.
Said HM; Kaya D; Yavuz I; Dost FS; Altun ZS; Isik AT
Clin Interv Aging; 2022; 17():467-477. PubMed ID: 35431542
[TBL] [Abstract][Full Text] [Related]
72. [Cerebrospinal fluid and plasma biomarkers for dementia with lewy bodies].
Kasuga K; Ikeuchi T
Brain Nerve; 2012 May; 64(5):505-13. PubMed ID: 22570064
[TBL] [Abstract][Full Text] [Related]
73. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
[TBL] [Abstract][Full Text] [Related]
74. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
[TBL] [Abstract][Full Text] [Related]
75. Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia.
Vallortigara J; Whitfield D; Quelch W; Alghamdi A; Howlett D; Hortobágyi T; Johnson M; Attems J; O'Brien JT; Thomas A; Ballard CG; Aarsland D; Francis PT
J Alzheimers Dis; 2016; 50(1):101-10. PubMed ID: 26639969
[TBL] [Abstract][Full Text] [Related]
76. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage.
Bousiges O; Bombois S; Schraen S; Wallon D; Quillard MM; Gabelle A; Lehmann S; Paquet C; Amar-Bouaziz E; Magnin E; Miguet-Alfonsi C; Delbeuck X; Lavaux T; Anthony P; Philippi N; Blanc F;
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):467-475. PubMed ID: 29321140
[TBL] [Abstract][Full Text] [Related]
77. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
[TBL] [Abstract][Full Text] [Related]
78. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM
Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965
[TBL] [Abstract][Full Text] [Related]
79. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage.
Bousiges O; Philippi N; Lavaux T; Perret-Liaudet A; Lachmann I; Schaeffer-Agalède C; Anthony P; Botzung A; Rauch L; Jung B; de Sousa PL; Demuynck C; Martin-Hunyadi C; Cretin B; Blanc F
Alzheimers Res Ther; 2020 Sep; 12(1):120. PubMed ID: 32993772
[TBL] [Abstract][Full Text] [Related]
80. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.
Nabizadeh F; Pirahesh K; Valizadeh P
J Neurol; 2022 Sep; 269(9):4836-4845. PubMed ID: 35426534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
